DNA News and Research

RSS

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

New, affordable technology for cervical cancer screening

Current cervical cancer screening is time consuming and expensive, but now new breakthrough technology developed by European researchers should allow large-range screening by non-medical personnel with almost immediate results and at a much lower cost.

15 Oct 2010

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.

14 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Scientists identify root cause of chromosomal errors and gene diversity

A team led by a scientist at the University of Pittsburgh School of Medicine has discovered a regulatory protein that influences where genetic material gets swapped between maternal and paternal chromosomes during the process of creating eggs and sperm. The findings, which shed light on the roots of chromosomal errors and gene diversity, appear in tomorrow's issue of Nature.

14 Oct 2010

Federal guidance aims to reduce misuse of synthetic DNA to create dangerous organisms

Federal guidance issued today aims to reduce the risk that synthetic DNA will be misused deliberately to create dangerous organisms. Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA, issued by the U.S. Department of Health and Human Services, supports national biosecurity goals and balances the promise of synthetic DNA with its potential biosecurity risks.

14 Oct 2010

Dyadic International receives sixth USPTO patent

Dyadic International, Inc. a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,794,962 by the United States Patent and Trademark Office.

14 Oct 2010

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc. a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

13 Oct 2010

Detect-Ready MRSA assay receives first independent validation

Molecular Detection Inc. a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George's Healthcare NHS Trust, a leading teaching hospital in the UK.

13 Oct 2010

Cancer Research UK launches programme to turn genetic revolution into better treatment for cancer patients

Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.

13 Oct 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Commercial genetic profiling services should provide detailed information about test results: Report

Direct-to-consumer personal genetic profiling services that claim to predict people's health risks by analysing their DNA are often inconclusive and companies that sell them should provide better information about the evidence on which the results are based, says the UK Nuffield Council on Bioethics, in a new report on the ethics of so-called personalised healthcare services.

13 Oct 2010

Cellectis bioresearch establishes US subsidiary

Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis, today announced that it has established a US subsidiary, Cellectis bioresearch Inc. Located at the Cambridge Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. will be responsible for the US-wide promotion of Cellectis bioresearch products and services.

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Akonni receives NIJ grant to develop HCID system for SNP identification

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for diagnosing complex infectious and human diseases, today announced receipt of a nearly $500,000 Phase III Grant from the National Institutes of Justice (NIJ).

13 Oct 2010

Defect in 21st amino acid leads to progressive brain atrophy: Study

A research team at Ben-Gurion University of the Negev and Soroka University Medical Center in Beer-Sheva, Israel has detected a genetic mutation resulting in a progressive disease of severe mental retardation and epilepsy beginning at infancy. The research was just published in the American Journal of Human Genetics.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Rad51 protein plays a key role in DNA protection

Cancer Research UK scientists have shed new light on the vital role that a protein plays in protecting our DNA, reveals a study published in Nature Structural and Molecular Biology today.

12 Oct 2010

DNA News and Research

Further Reading

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

New, affordable technology for cervical cancer screening

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Scientists identify protein in urine can indicate prostate cancer risk

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Scientists identify root cause of chromosomal errors and gene diversity

Federal guidance aims to reduce misuse of synthetic DNA to create dangerous organisms

Dyadic International receives sixth USPTO patent

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

Detect-Ready MRSA assay receives first independent validation

Cancer Research UK launches programme to turn genetic revolution into better treatment for cancer patients

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Commercial genetic profiling services should provide detailed information about test results: Report

Cellectis bioresearch establishes US subsidiary

New evidence supports possible link between XMRV and prostate cancer

Akonni receives NIJ grant to develop HCID system for SNP identification

Defect in 21st amino acid leads to progressive brain atrophy: Study

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

Rad51 protein plays a key role in DNA protection

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News